Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 60, Issue 8, 2009, Pages 2438-2447

  Holvast, Albert ^a   Van Assen, Sander ^a   De Haan, Aalzen ^a   Huckriede, Anke ^a   Benne, Cornelis A ^b   Westra, Johanna ^a   Palache, Abraham ^c   Wilschut, Jan ^a   Kallenberg, Cees G M ^a   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Laboratory for Infectious Diseases   (Netherlands)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; INTERLEUKIN 2; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TEST; HOST RESISTANCE; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEROCONVERSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; FEMALE; HEALTH STATUS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 68049091012     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24679     Document Type: Article

References (41)

1. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002;16:281-91.
2. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102:55-60.
3. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-28.
4. Abu-Shakra M, Press J, Buskila D, Sukenik S. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun Rev 2007;6:543-6.
5. Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008;46:1459-65.
6. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913-8.
7. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-9.
8. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine 2005;23 Suppl 1:S26-S38.
9. Vogt A, Mahe B, Costagliola D, Bonduelle O, Hadam S, Schaefer G, et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008;180:1482-9.
10. Bermas BL, Petri M, Goldman D, Mittleman B, Miller MW, Stocks NI, et al. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 1994;14:169-77.
11. Pons VG, Reinertsen JL, Steinberg AD, Dolin R. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol 1979;4:15-23.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Influenza vaccines. Wkly Epidemiol Rec 2005;80:279-87.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, for the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
15. Long BR, Michaelsson J, Loo CP, Ballan WM, Vu BA, Hecht FM, et al. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol 2008;15:120-30.
16. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006;3:361-8.
17. Harmon MW. Influenza virus. In: Lennette EH, Smith TF, editors. Laboratory diagnosis of viral infection. 3rd ed. New York: Marcel Dekker, Inc.; 1999. p. 587-601.
18. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products; March 12, 1997.
19. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003;283:141-53.
20. Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, et al. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 2008;124:155-65.
21. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-53.
22. Cheong HJ, Song JY, Park JW, Yeon JE, Byun KS, Lee CH, et al. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 2006;24:2417-22.
23. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004;172:3437-46.
24. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
25. Draeger AM, Swaak AJ, van den Brink HG, Aarden LA. T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2. Clin Exp Immunol 1986;64:80-7.
26. Nies K, Boyer R, Stevens R, Louie J. Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus: comparison of the in vitro and in vivo responses. Arthritis Rheum 1980;23:1343-50.
27. Gottlieb AB, Lahita RG, Chiorazzi N, Kunkel HG. Immune function in systemic lupus erythematosus: impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen. J Clin Invest 1979;63:885-92.
28. Hernandez-Fuentes MP, Reyes E, Prieto A, Zea A, Villa L, Sanchez-Atrio A, et al. Defective proliferative response of T lymphocytes from patients with inactive systemic lupus erythematosus. J Rheumatol 1999;26:1518-26.
29. Lockshin MD, Eisenhauer AC, Kohn R, Weksler M, Block S, Mushlin SB. Cell-mediated immunity in rheumatic diseases. II. Mitogen responses in RA, SLE, and other illnesses: correlation with T- and B-lymphocyte populations. Arthritis Rheum 1975;18:245-50.
30. Defreitas ME, Kondracki E, Perez-Rojas G, Bianco NE. Further aspects of T cell function in systemic lupus erythematosus. Immunol Commun 1982;11:113-20.
31. Stekman IL, Blasini AM, Leon-Ponte M, Baroja ML, Abadi I, Rodriguez MA. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Arthritis Rheum 1991;34:459-67.
32. Via CS, Tsokos GC, Bermas B, Clerici M, Shearer GM. T cell-antigen-presenting cell interactions in human systemic lupus erythematosus: evidence for heterogeneous expression of multiple defects. J Immunol 1993;151:3914-22.
33. Scheinecker C, Zwolfer B, Koller M, Manner G, Smolen JS. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001;44:856-65.
34. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people: a randomized double-blind placebo-controlled trial. Vaccine 1994;12:1185-9.
35. Gross PA, Sperber SJ, Donabedian A, Dran S, Morchel G, Cataruozolo P, et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999;17:2284-9.
36. Pyhala R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994;12:947-52.
37. De Bruijn I, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999;179:31-6.
38. Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988;127:353-64.
39. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997;15:1114-22.
40. De Bruijn I, Remarque EJ, Beyer WE, le Cessie S, Masurel N, Ligthart GJ. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. Vaccine 1997;15:1323-9.
41. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008;112:1570-80.